Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Anderson

Showing results (101-110 of 868) with videos related to

Pageof 87
Sort By:
Expert Review of Anticancer Therapy|October 6, 2006
Therapeutic use of immunomodulatory drugs in the treatment of multiple myelomaNoopur Raje, Teru Hideshima, Kenneth C Anderson
Advances in Experimental Medicine and Biology|April 29, 2008
Targeting proteasomes as therapy in multiple myelomaDharminder Chauhan, Teru Hideshima, Kenneth C Anderson
Blood Cancer Journal|October 7, 2021
Author Correction: The biological significance of histone modifiers in multiple myeloma: clinical applicationsHiroto Ohguchi, Teru Hideshima, Kenneth C Anderson
Experimental Hematology|June 30, 2015
Novel therapeutic strategies for multiple myelomaNaoya Mimura, Teru Hideshima, Kenneth C Anderson
Immunological Reviews|July 9, 2003
Novel therapeutic approaches for multiple myelomaTeru Hideshima, Paul Richardson, Kenneth C Anderson
International Journal of Hematology|September 5, 2003
Apoptotic signaling in multiple myeloma: therapeutic implicationsDharminder Chauhan, Teru Hideshima, Kenneth C Anderson
Annual Review of Pharmacology and Toxicology|April 12, 2005
Proteasome inhibition in multiple myeloma: therapeutic implicationDharminder Chauhan, Teru Hideshima, Kenneth C Anderson
Oncotarget|January 8, 2019
PRMT5 inhibitors on the (myeloma) roadAnnamaria Gulla, Teru Hideshima, Kenneth C Anderson
Molecular & Cellular Oncology|June 17, 2016
Awakening the Hippo co-activator YAP1, a mercurial cancer gene, in hematologic cancersFrancesca Cottini, Kenneth C Anderson, Giovanni Tonon
Blood Reviews|December 4, 2010
Multiple myeloma: biology of the diseaseAnuj Mahindra, Teru Hideshima, Kenneth C Anderson
Pageof 87

Showing results (101-110 of 868) with videos related to

Sort By:
Pageof 87
Expert Review of Anticancer Therapy|October 6, 2006
Therapeutic use of immunomodulatory drugs in the treatment of multiple myelomaNoopur Raje, Teru Hideshima, Kenneth C Anderson
Advances in Experimental Medicine and Biology|April 29, 2008
Targeting proteasomes as therapy in multiple myelomaDharminder Chauhan, Teru Hideshima, Kenneth C Anderson
Blood Cancer Journal|October 7, 2021
Author Correction: The biological significance of histone modifiers in multiple myeloma: clinical applicationsHiroto Ohguchi, Teru Hideshima, Kenneth C Anderson
Experimental Hematology|June 30, 2015
Novel therapeutic strategies for multiple myelomaNaoya Mimura, Teru Hideshima, Kenneth C Anderson
Immunological Reviews|July 9, 2003
Novel therapeutic approaches for multiple myelomaTeru Hideshima, Paul Richardson, Kenneth C Anderson
International Journal of Hematology|September 5, 2003
Apoptotic signaling in multiple myeloma: therapeutic implicationsDharminder Chauhan, Teru Hideshima, Kenneth C Anderson
Annual Review of Pharmacology and Toxicology|April 12, 2005
Proteasome inhibition in multiple myeloma: therapeutic implicationDharminder Chauhan, Teru Hideshima, Kenneth C Anderson
Oncotarget|January 8, 2019
PRMT5 inhibitors on the (myeloma) roadAnnamaria Gulla, Teru Hideshima, Kenneth C Anderson
Molecular & Cellular Oncology|June 17, 2016
Awakening the Hippo co-activator YAP1, a mercurial cancer gene, in hematologic cancersFrancesca Cottini, Kenneth C Anderson, Giovanni Tonon
Blood Reviews|December 4, 2010
Multiple myeloma: biology of the diseaseAnuj Mahindra, Teru Hideshima, Kenneth C Anderson
Pageof 87